WARD Medication Management (WardMM) has signed a clinical trial agreement with LeafCann Research & Advisory, which will see the cannabis group sponsor research and provide medicinal marijuana extracts for a WardMM project looking at a potential new option for the treatment of dementia.
As well as looking at the behavioural and psychological symptoms of dementia (BPSD), the organisations will also work on the development of a foundational medicinal cannabis R&D program to investigate safer medication use of other derivatives for a range of clinically important outcomes.
WardMM group ceo Stuart Ward said with the company's "exciting clinical decision support systems and our clinical capability we may be able to reduce the side effects, shape safer medication regimes and provide a better quality of life for patients living with BPSD, as well as their families".
Prominent pharmacists involved with WardMM include Chris Alderman and Natalie Soulsby - more info at www.leafcann.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Dec 17
